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Objective: To investigate the inﬂuence of Notch signaling on osteoprotegerin (OPG)
expression in a human oral squamous cell carcinoma cell line.
Methods: Activation of Notch signaling was performed by seeding cells on Jagged1
immobilized surfaces. In other experiments, a g-secretase inhibitor was added to the
culture medium to inhibit intracellular Notch signaling. OPG mRNA and protein were
determined by real-time PCR and ELISA, respectively. Finally, publicly available
microarray database analysis was performed using connection up- or down-regulation
expression analysis of microarrays software.
Results: Jagged1-treatment of HSC-4 cells enhanced HES1 and HEY1 mRNA expres-
sion, conﬁrming the intracellular activation of Notch signaling. OPG mRNA and protein
levels were signiﬁcantly suppressed upon Jagged1 treatment. Correspondingly, HSC-4
cells treated with a g-secretase inhibitor resulted in a signiﬁcant reduction of HES1
and HEY1 mRNA levels, and a marked increase in OPG protein expression was observed.
These results implied that Notch signaling regulated OPG expression in HSC-4 cells.
However, Jagged1 did not alter OPG expression in another human oral squamous cell
carcinoma cell line (HSC-5) or a human head and neck squamous cell carcinoma cell line
(HN22).
Conclusions: Notch signaling regulated OPG expression in an HSC-4 cell line and this
mechanism could be cell line speciﬁc.1. Introduction
Osteoprotegerin (OPG) is a decoy receptor regulating re-
ceptor and ligand interaction [1]. OPG is known to interact withreceptor activator of nuclear factor kappa-B ligand (RANKL)
and tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL), however, high-afﬁnity binding was demonstrated for
RANKL [1]. The role of OPG in osteoclastogenesis is well
documented. OPG deﬁcient mice exhibit a severe and early-
onset osteoporosis phenotype as well as a high incidence of
fractures [2]. Correspondingly, OPG transgenic mice that
contained the human OPG promoter had signiﬁcantly
increased bone mass in cortical and trabecular bone [3]. In
addition to the effect on bone phenotypes, OPG deﬁcient mice
demonstrate high aorta and renal artery calciﬁcation, implying
the role of OPG in regulating pathological calciﬁcation [2].
Furthermore, OPG regulates other biological events, such as
immune response, cell survival, and osteoblastic differentiation
[1,4,5].
In cancer biology, OPG participates in bone invasion and
apoptosis of cancer cells. OPG inhibits TRAIL-induced
apoptosis in several types of cancers, including ovarian can-
cer cells, breast cancer cells, and colon cancer cells [6–8]. Article under the CC BY-NC-ND license (http://
Table 1
Primer sequences.
Gene Primer sequences Accession no.
GAPDH F 50-TCATGGGTGTGAACCATGAGAA-30 NM_002046.3
R 50-GGCATGGACTGTGGTCATGAG-30
OPG F 50-AGCTGCAGTACGTCAAGCAGGA-30 NM_002546.3
R 50-TTTGCAAACTGTATTTCGCTCTGG-30
HES1 F 50-AGGCGGACATTCTGGAAATG-30 NM_005524.2
R 50-CGGTACTTCCCCAGCACACTT-30
HEY1 F 50-CTGCAGATGACCGTGGATCA-30 NM_012258.3
R 50-CCAAACTCCGATAGTCCATAGCAA-30
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; F: Forward; R:
Reverse.
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expression and TRAIL-induced cell apoptosis was observed
in prostate cancer [9]. Exogenous OPG enhanced the
proliferation of an osteosarcoma cell line partly via the
nuclear factor kappa-B signaling pathway [10]. Further, a
high RANKL/OPG ratio in human non-small cell lung can-
cer correlated with higher metastatic ability [11]. OPG also
promotes endothelial cell survival and vessel formation [12].
Moreover, endothelial cells in malignant lesions express
higher OPG levels than those in non-malignant tumors,
implying the role of OPG in cancer angiogenesis [12]. Taken
together, these data suggest a signiﬁcant role of OPG in
cancer cell behavior.
In oral cancer, OPG administration led to decreased
mandibular bone invasion by transplanted human oral squamous
cell carcinoma (OSCC) cells in nude mice [13]. In addition, OPG
injected mice exhibit higher terminal deoxynucleotidyl
transferase dUTP nick end labeling positive cancer cells
compared with the control group, indicating that OPG
promotes OSCC cell apoptosis [13]. Furthermore, OPG
signiﬁcantly inhibits RANKL-induced OSCC cell migration
in vitro [13]. Another report indicated that OSCC promotes bone
invasion via the suppression of OPG expression in the host
stromal cells [14]. These results imply an important function of
OPG in OSCC cell behavior.
Notch signaling is a highly conserved signaling pathway
that regulates various cell functions in development, disease,
and regenerative processes. It has been shown that Notch
signaling regulates OSCC cell behavior [15,16]. In addition to
the roles of Notch signaling in OSCC, it has been
demonstrated that Notch signaling regulates OPG expression
in osteocytes [17]. However, the relationship between Notch
signaling and OPG expression in human OSCC cells remains
unknown. Thus, the present study investigated the regulation
of OPG expression by Notch signaling in a human OSCC
cell line.
2. Materials and methods
2.1. Cell culture and treatment
Two human OSCC cell lines (HSC-4 and HSC-5) and one
HNSCC cell line (HN22) were used in the present study. The
HSC-4 and HSC-5 cell lines were gifts from Professor Teuro
Amagasa (Tokyo Medical and Dental University, Japan). The
HN22 cell line was kindly provided by Professor J. Silvio
Gutkind (National Institute of Dental and Craniofacial Research,
National Institutes of Health, USA). The cells were maintained
in Dulbecco's modiﬁed Eagle's medium containing 10% fetal
bovine serum, 2 mmol/L L-glutamine, 100 unit/mL penicillin,
100 mg/mL streptomycin, and 250 ng/mL amphotericin B at
37 C in a humidiﬁed 5% carbon dioxide atmosphere. All cell
culture reagents were purchased from Gibco BRL (Carlsbad,
USA).
For Notch signaling activation, Jagged1 immobilization on
tissue culture surfaces was performed according to our previous
publication [18]. Brieﬂy, tissue culture plates were coated with
recombinant protein G (50 mg/mL) for 16 h, followed by
bovine serum albumin (10 mg/mL) for 2 h and recombinant
human Jagged-1/Fc (R & D systems, USA) for 2 h. Thesurfaces were washed with sterile phosphate buffer solution
between each step. Subsequently, 75 000 cells/well were seeded
on the Jagged-1 modiﬁed surfaces in 24-well plates and main-
tained in culture medium for 48 h. For the inhibition experiment,
the cells were seeded on 24-well plates as described above and
treated with a g-secretase inhibitor (DAPT 20 mmol/L, Sigma–
Aldirch, USA) for 48 h.
2.2. ELISA
Culture medium was collected 48 h after treatment and used
to determine the secreted OPG levels. OPG protein expression
was measured using a human OPG/TNFRSF11B DuoSet kit R
& D Systems, USA) according to the manufacturer's in-
structions. The absorbance was examined at 450 nm. The re-
sults were normalized to the control and presented as fold
change.
2.3. Real-time PCR
Total cellular RNA was isolated using Isol-RNA Lysis
reagent (5 Prime, USA). RNA (1 mg) was converted to cDNA
using a reverse transcriptase kit (Promega, USA). FastStart®
Essential DNA Green Master (Roche Applied Science, Indi-
anapolis, IN, USA) was employed for PCR in a Lightcycler
Nano realtime PCR machine (Roche Applied Science, USA).
The expression values were normalized to glyceraldehyde-3-
phosphate dehydrogenase expression and then normalized
to the control results. The primer sequences are shown in
Table 1.2.4. Microarray database analysis
Publicly available microarray expression database analysis
was performed using connection up- or down-regulation
expression analysis of microarrays software [19,20]. Brieﬂy, the
microarray dataset Gene Expression Omnibus (GEO) series
were identiﬁed using the keywords “JAG1 or Jagged1”. The
expression proﬁle studies in human cancer cells containing
three or more samples in each experimental group were
included in our analysis. The GEO series and their
platforms (GSE14995 and GSE36051) were downloaded from
the GEO repository [21]. The differential expression of OPG
(TNFRSF11B) mRNA was evaluated. Statistical analysis was
performed using the two independent samples student's t-test,
which is an extension of the connection up- or down-
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Differences at P < 0.05 were considered to be statistically
signiﬁcant.
2.5. Statistical analyses
The data were presented as box and whisker plots. The
Mann–Whitney U test was employed to determine statistical
differences. Differences at P < 0.05 were considered to be sta-
tistically signiﬁcant.
3. Results
3.1. Attenuation of OPG expression in HSC-4 cells by
Notch signaling activation
To activate intracellular Notch signaling, HSC-4 cells were
seeded on Jagged1 immobilized surfaces. At 48 h, a signiﬁcant
increase in Notch target gene (HES1 and HEY1) mRNA levels
was observed (Figure 1A, B), implying successful Notch
activation. Interestingly, Jagged1 treated HSC-4 cells exhibited
a signiﬁcant decrease in OPG expression at both the mRNA
and protein levels (Figure 1C, D).
To further conﬁrm the inﬂuence of Notch signaling on OPG
expression by HSC-4 cells, a g-secretase inhibitor (DAPT) was
employed to inhibit the cleavage of the Notch receptor, leading
to the attenuation of intracellular Notch signaling. The results
demonstrated that DAPT inhibited HES1 and HEY1 mRNA
expression (Figure 2A, B). Consistent with these ﬁndings,
DAPT treatment promoted OPG expression (Figure 2C, D).2.0
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Figure 1. HSC-4 cells seeded on Jagged1 immobilized surfaces for 48 h.
The mRNA expression was determined using real-time PCR (A–C) and protein
difference compared to the control.
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Figure 2. HSC-4 cells treated with a g-secretase inhibitor (DAPT) for 48 h.
The mRNA expression was determined using real-time PCR (A–C) and protein
difference compared to the control.This result may imply the role of endogenous Notch signaling
in OPG expression in HSC-4 cells.
3.2. Effect of Jagged1 treatment on OPG expression in
other human cancer cell line studies
To determine whether the role of Jagged1 attenuated OPG
expression depended on cell type, a publicly available micro-
array database screening was evaluated. The investigations
where human cancer cells overexpressed Jagged1 or were
seeded on Jagged1 immobilized surfaces were included in our
analysis (Table 2). In the database, there were only two studies
that matched the inclusion criteria. These studies were per-
formed using a human lung cancer cell line (CL1-0) or human
breast cancer cell lines (MCF7 and MDA-MB-231). The results
showed that there was no signiﬁcant difference in OPG levels in
the cell lines either overexpressing Jagged1 or exposed to Jag-
ged1 immobilized surfaces, implying a cell type speciﬁc role of
Jagged1 on OPG expression.
3.3. Speciﬁc inﬂuence of Jagged1 on OPG expression in
OSCC cells
To determine the speciﬁc inﬂuence of Jagged1 on OPG
expression in OSCC cells, an OSCC cell line (HSC-5), and an
HNSCC cell line (HN22) were employed. The results showed
that Jagged1 immobilized surfaces successfully activated Notch
signaling in these cells as determined by the signiﬁcant upre-
gulation of Notch target genes (HES1 and HEY1) (Figure 3).
However, no alterations in OPG mRNA or protein levels were1.2
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Table 2
Expression of OPG (TNFRSF11B) in the control and the overexpressing Jagged1 or immobilized Jagged1/Fc exposed groups.
GEO series Probe ID Conditions Expression value (Mean ± SD) P-value
GSE14995
Human lung adenocarcinoma cell line (CL1-0)
Control group: CL1-0 cells (n = 3)
Experimental group: Jagged1
overexpressing cells (n = 3)
204932_at Control group 0.880 ± 0.067 0.334
Experimental group 0.830 ± 0.046
204933_s_at Control group 0.510 ± 0.003 0.817
Experimental group 0.510 ± 0.011
GSE36051
Human breast cancer cell line
(MCF7, ER+, wild-type p53,
luminal type B breast cancer)
Control group: Cells on Fc coated
surfaces with dimethyl sulfoxide
vehicle control (n = 3)
Experimental group: Cells on
Jagged1/Fc coated surfaces (n = 3)
ILMN_1676663 Control group 20.140 ± 0.235 0.423
Experimental group 20.000 ± 0.000
GSE36051
Human breast cancer cell line
(MDA-MB-231, ER−, mutated p53,
basal breast cancer)
Control group: Cells on Fc coated
surfaces with dimethyl sulfoxide
vehicle control (n = 3)
Experimental group: Cells on
Jagged1/Fc coated surfaces (n = 3)
ILMN_1676663 Control group 20.020 ± 0.041 0.443
Experimental group 20.460 ± 0.790
Experimental group 56.530 ± 22.880
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Figure 3. The human primary oral squamous cell carcinoma cell line (HSC-5) and human head and neck squamous cell carcinoma cell line (HN22) seeded
on Jagged1 immobilized surfaces for 48 h.
The mRNA expression was determined using real-time PCR (A–C and E–G) and protein expression was measured using ELISA (D and H). Asterisks
indicate a signiﬁcant difference compared to the control.
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mechanism regulating OPG expression was cell type speciﬁc.
4. Discussion
Several studies have demonstrated the role of OPG in OSCC.
Immunohistochemistry analysis revealed that OSCC expressed
OPG, while OPG staining was not observed in normal buccal
mucosa [22]. However, there was no signiﬁcant difference in
OPG expression between OSCC with or without bone
invasion [22]. Another study indicated a relationship between
OPG expression and OSCC aggressiveness. It was observedthat tumor samples from patients with malignant bone
invasion expressed higher OPG levels than those of patients
without bone invasion [23]. Correspondingly, an animal study
showed that OPG administration decreased mandibular bone
invasion by transplanted human OSCC cells [13]. Together,
these studies may imply the inﬂuence of OPG in regulating
OSCC behavior.
The present study demonstrated that the activation of Notch
signaling attenuated OPG expression and Notch signaling inhi-
bition resulted in increased OPG mRNA levels in an HSC-4 cell
line. There are several hypotheses that may explain the role of
Notch-regulated OPG in OSCC. First, Notch and OPG may
Jeeranan Manokawinchoke et al./Asian Pac J Trop Biomed 2016; 6(8): 692–697696regulate the bone invasion by OSCC similar to their modulation
of osteoclastogenesis. OPG treatment of mice transplanted with
human OSCC cells in resulted in reduced mandibular bone in-
vasion [13]. Decreased TRAP positive multinucleated cells were
demonstrated in the OPG treated groups [13]. Jagged1, a Notch
ligand, was shown to promote osteoclast formation and
function [24]. Thus, Notch activation in HSC-4 cells led to the
reduction of OPG expression and may participate in the
enhancement of bone invasion by these cells. Second, Notch
regulation of OPG expression may be involved in the control of
cancer cell migration. It was shown that Notch signaling was
involved in hypoxia-induced OSCC cell migration and invasion
[15]. However, OPG inhibited RANKL-induced OSCC cell
migration [13]. Together, these results imply that Notch
attenuated OPG expression in HSC-4 cells promotes OSCC
cell migration. Third, Notch modulation of OPG expression may
be involved in the control of cancer cell apoptosis. It was
demonstrated that Notch signaling inhibition by DAPT treat-
ment in a human tongue carcinoma cell line resulted in the in-
hibition of Notch target gene (HES1) expression and the
promotion of cell apoptosis [25]. In contrast, OPG administration
led to increased cell apoptosis in an OSCC invaded bone model
in vivo, but the in vitro portion of this study revealed no
inﬂuence of OPG on OSCC cell apoptosis [13]. Therefore, the
effect of OPG on cell apoptosis may be limited to the bone
microenvironment in vivo. However, it could be hypothesized
that Notch signaling activation leads to decreased OPG
expression, resulting in decreased cell apoptosis. Further
investigation is needed to conﬁrm these hypotheses.
In the present study, the inﬂuence of Notch signaling on OPG
expression was demonstrated in HSC-4 cells, but not in other
cell lines (HSC-5 and HN-22). These results may imply that the
role of Notch signaling on OPG expression may occur only in
speciﬁc cell types. We focused on an OSCC derived cell line
(HSC-4) that was derived from a lymph node metastasis that
originated from the tongue. The HSC-5 cells were derived from
a primary lesion at the maxillary sinus area. Previously, it has
been shown that increased OPG expression in OSCC correlated
with local bone invasion, poor response to neoadjuvant che-
moradiotherapy, and decreased patient survival [23]. Thus, Notch
regulated OPG expression in HSC-4 cells but not in HSC-5 cells
may be due to different regulation of cell behavior between
invasive and primary lesion derived cell lines.
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